

- **Name:** Samuel Klempner
  - **Current Position & Affiliation:** Associate Professor, Director of Gastroesophageal Medical Oncology, Massachusetts General Hospital, Boston, MA
  - **Country:** USA
- 

• **Educational Background:**

- **Residency:** Brigham and Women's Hospital, Harvard Medical School
- **Fellowship:** Beth Israel Deaconess Medical Center, Harvard Medical School

• **Professional Experience:**

I am a gastrointestinal medical oncologist with a clinical and research focus in upper GI cancers, specifically gastroesophageal and colorectal cancers. I currently lead the gastroesophageal program at the MGH Cancer Center. My own translational research is centered on identification of molecular subgroups and heterogeneity in GI cancers and translation of these findings to therapeutic clinical trials. I co-chair the NCI task force for esophagogastric cancers and serve on the national guideline committees (NCCN) for stomach, GEJ, and esophageal cancers, and the NRG non-colorectal research subcommittee. I am a PI and/or co-investigator on multiple industry and investigator-initiated targeted therapy and immunotherapy trials in gastric and esophageal cancers.

**Positions and Scientific Appointments**

2024 – Present	Associate Editor, Journal of Clinical Oncology, Precision Oncology
2023 – Present	Co-Chair, NCI Esophagogastric Task Force
2023 – Present	Director of Gastroesophageal Medical Oncology, Massachusetts General Hospital
2023 – Present	Scientific Track Lead, non-colorectal, ASCO Annual Meeting Scientific committee
2021 – Present	Associate Professor of Medicine, Harvard Medical School
2020 – Present	Member, American Gastroenterological Association (AGA)
2020 – Present	Associate Scientist, Broad Institute of Harvard and MIT
2020 -- Present	Member, NRG Non-colorectal committee
2020 – Present	Member, NCI Esophagogastric Task Force
2019 – Present	Member, NCCN guideline panel, Gastric and Esophageal Cancers
2019 – Present	Editorial Board Member, JCO Precision Oncology
2019 – Present	Scientific-Medical Advisory Board, Debbie's Dream Foundation
2019 – Present	Affiliate Researcher, Broad Institute of MIT and Harvard
2019 – Present	Chair, Medical Advisory Board, Hope for Stomach Cancer
2019 – 2021	Member of the Faculty, Massachusetts General Hospital, Harvard Medical School
2017 – Present	Ad-Hoc Reviewer, NCI Clinical Trial Working Group (CTWG)
2016 – Present	Member, ASCO TAPUR Molecular Tumor Board
2016 – 2019	Director of Precision Medicine and GI Oncology, The Angeles Clinic, Los Angeles, CA
2015 – Present	CDMRP (Department of Defense) PRCRP GIC (Gastrointestinal Cancers)
2013 – Present	Member, European Society of Medical Oncology (ESMO)
2013 – 2016	Assistant Professor of Medicine, University of California Irvine, Orange, CA
2012 – Present	Member, American Association of Cancer Research (AACR)

2011 – 2013      Research Fellow, Department of Signal Transduction, Beth Israel Deaconess Medical Center, Boston, MA (Principal Investigator, Lewis C. Cantley, PhD)  
2010 – Present   Member, American Society of Clinical Oncology (ASCO)

# Professional Organizations:

ASCO,  
AACR,  
ESMO,  
ISDE (International Society for Diseases of the Esophagus),  
ISSPP (International Society for the Study of the Pleura and Peritoneum)

# Main Scientific Publications:

1. An M, Mehta A, Min BH, Heo YJ, Wright SJ, Parikh M, Bi L, Lee H, Kim TJ, Lee SY, Moon J, Park RJ, Strickland MR, Park WY, Kang WK, Kim KM, Kim ST, **Klempner SJ**, Lee J. Early immune remodeling steers clinical response to frontline chemoimmunotherapy in advanced gastric cancer. *Cancer Discov.* 2024 Feb 6. doi: 10.1158/2159-8290.CD-23-0857. Epub ahead of print. PMID: 38319303.
2. **Klempner SJ**, Sonbol MB, Wainberg ZA, Uronis HE, Chiu VK, Scott AJ, Iqbal S, Tejani MA, Chung V, Stilian MC, Thoma M, Zhang Y, Kagey MH, Baum J, Sirard CA, Altura RA, Ajani JA. DKN-01 in Combination With Tislelizumab and Chemotherapy as First-Line Therapy in Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: DisTinguish. *J Clin Oncol.* 2024 Oct 21:JCO2400410. doi: 10.1200/JCO.24.00410. Epub ahead of print. PMID: 39432867.
3. Maron SB, Moya S, Morano F, Emmett MJ, Chou JF, Sabwa S, Walch H, Peterson B, Schrock AB, Zhang L, Janjigian YY, Chalasani S, Ku GY, Disel U, Enzinger P, Uboha N, Kato S, Yoshino T, Shitara K, Nakamura Y, Saeed A, Kasi P, Chao J, Lee J, Capanu M, Wainberg Z, Petty R, Pietrantonio F, **Klempner SJ**, Catenacci DVT. Epidermal Growth Factor Receptor Inhibition in Epidermal Growth Factor Receptor-Amplified Gastroesophageal Cancer: Retrospective Global Experience. *J Clin Oncol.* 2022 Mar 29:JCO2102453. Epub ahead of print. PMID: 35349370.
4. Yaeger R, Weiss J, Pelster MS, Spira AI, Barve M, Ou SI, Leal TA, Bekaii-Saab TS, Paweletz CP, Heavey GA, Christensen JG, Velastegui K, Kheoh T, Der-Torossian H, **Klempner SJ**. Adagrasib with or without Cetuximab in Colorectal Cancer with Mutated *KRAS* G12C. *N Engl J Med.* 2023 Jan 5;388(1):44-54. PMID: 36546659.
5. Kwon M,\* An M\*, **Klempner SJ\***, Lee H, Kim KM, Sa JK, Cho HJ, Hong JY, Lee T, Min YW, Kim TJ, Min BH, Park WY, Kang WK, Kim KT, Kim ST, Lee J. Determinants of Response and Intrinsic Resistance to PD-1 Blockade in Microsatellite Instability-High Gastric Cancer. *Cancer Discov.* 2021 Sep;11(9):2168-2185. PMID: 33846173. \*co-first authors
6. Kim R, An M, Lee H, Mehta A, Heo YJ, Kim KM, Lee SY, Moon J, Kim ST, Min BH, Kim TJ, Rha SY, Kang WK, Park WY, **Klempner SJ\***, Lee J\*. Early Tumor-Immune Microenvironmental Remodeling and Response to Frontline Fluoropyrimidine and Platinum Chemotherapy in Advanced Gastric Cancer. *Cancer Discov.* 2021. Epub ahead of print. PMID: 34933901. \*co-senior/corresponding
7. Zhao JJ, Johnny Ong CA, Srivatsava S, Ann Chia DK, Ma H, Huang K, Sheng T, Ramnarayanan K, Ong X, Tay ST, Hagihara T, Keng Tan AL, Ching Teo MC, Tan QX, Ng G, Wee-Shan Tan J, Hsien Ng MC, Gwee YX, Walsh R, Law JH, Shabbir A, Kim G, Tay Y, Her Z, Leoncini G, Teh BT, Hong JH, Kiat Tay RY, Teo CB, Dings MPG, Bijlsma M, Yew Lum JH, Mathur S, Pietrantonio F, Blum SM, van Laarhoven H, **Klempner SJ**, Yong WP, Yan So JB, Chen Q, Tan P, Sundar R. Spatially resolved niche and tumor microenvironmental

alterations in gastric cancer peritoneal metastases. *Gastroenterology*. 2024 Aug 13:S0016-5085(24)05348-4. doi: 10.1053/j.gastro.2024.08.007. Epub ahead of print. PMID: 39147169.

8. **Klempner SJ**, Lee KW, Shitara K, Metges JP, Lonardi S, Ilson DH, Fazio N, Kim TY, Bai LY, Moran D, Yang J, Arozullah A, Park JW, Raizer JJ, Bang YJ, Shah MA. ILUSTRO: Phase 2 Multicohort Trial of Zolbetuximab in Patients with Advanced or Metastatic Claudin 18.2-Positive Gastric or Gastroesophageal Junction Adenocarcinoma. *Clin Cancer Res*. 2023 Jul 25:CCR-23-0204. doi: 10.1158/1078-0432.CCR-23-0204. Epub ahead of print. PMID: 37490286.
9. Shitara K, Shah MA, Lordick F, Van Cutsem E, Ilson DH, **Klempner SJ**, Kang YK, Lonardi S, Hung YP, Yamaguchi K, Enzinger P, Nakajima T, Matsangou M, Cao Y, Li R, Moran D, Pophale R, Oh M, Ranganath R, Ajani JA, Xu RH. Zolbetuximab in Gastric or Gastroesophageal Junction Adenocarcinoma. *N Engl J Med*. 2024 Sep 26;391(12):1159-1162. doi: 10.1056/NEJMc2409512. Epub 2024 Sep 16. PMID: 39282934.